Foundation Fighting Blindness Fund Exits Major Stake in Opus Genetics
IRD has more than doubled off its 52-week low of $0.901.
Summary
A major institutional investor, Foundation Fighting Blindness, has sold a significant portion of its holdings in Opus Genetics, reducing its stake below 5% and filing an exit amendment to its Schedule 13D.
Key Events · Ownership and Investor Activity · IRD
-
Institutional Investor Exits Major Stake
Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. have reduced their beneficial ownership in Opus Genetics below the 5% threshold.
-
Significant Share Sale
This reduction follows a $7.395 million sale of common stock on May 18, 2026, as referenced in a related Form 4 filing.
-
Cessation of Reporting Obligations
The filing indicates this will be the final amendment to their Schedule 13D, terminating their reporting obligations under Section 13(d) of the Exchange Act.
Analysis · IRD · Life Sciences
Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. have filed an amendment to their Schedule 13D, indicating they have sold shares and will cease to be a beneficial owner of more than five percent of Opus Genetics' common stock. This "exit filing" follows a $7.395 million sale reported in a recent Form 4, signaling a significant reduction in their investment and a potential loss of confidence from a key institutional investor. This divestment occurs amidst recent capital raises and an increase in authorized shares by Opus Genetics.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRD was trading at $4.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $361.4M. The 52-week trading range was $0.90 to $5.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.